Lifordi Immunotherapeutics will present new preclinical data demonstrating that its lead antibody drug conjugate candidate LFD-200 achieves selective and sustained delivery of glucocorticoid payload to immune tissues without evidence of toxicity. The findings from multiple in vitro and in vivo studies in non-human primates show that LFD-200 provides targeted anti-inflammatory effects while maintaining a favorable safety profile at clinically relevant doses.
The data, to be presented at the American College of Rheumatology Convergence 2025 meeting in Chicago, represents a significant advancement in autoimmune disease treatment. LFD-200 selectively delivers glucocorticoid to immune cells and results in inhibition of ex vivo induced inflammatory cytokines without observed systemic toxicity. This targeted approach could provide the efficacy of traditional steroids while avoiding the widespread side effects that often limit their long-term use.
For patients living with autoimmune and inflammatory diseases such as rheumatoid arthritis, this development could mean access to a safer, less frequently dosed glucocorticoid treatment option. Current steroid treatments often cause systemic side effects including weight gain, mood changes, osteoporosis, and increased infection risk when used long-term. The selective delivery mechanism of LFD-200 addresses these limitations by concentrating the drug's effects specifically on immune cells involved in disease pathology.
The preclinical results show consistent performance across multiple studies, with LFD-200 providing sustained anti-inflammatory effects in non-human primates. The antibody drug conjugate targets myeloid and lymphoid cells using VISTA, a highly internalized cell surface membrane protein. This targeting mechanism allows the glucocorticoid payload to reach the precise immune cells driving inflammation while sparing other tissues from exposure.
Lifordi Immunotherapeutics is currently evaluating LFD-200 in a Phase 1 clinical trial, building on the promising preclinical data. The company's approach represents a novel application of antibody drug conjugate technology, which has previously shown success in cancer treatment, now adapted for autoimmune and inflammatory conditions. Additional information about the company's research can be found at https://www.lifordi.com.
The presentation of these findings at the ACR Convergence 2025 meeting underscores the growing interest in targeted therapies for autoimmune diseases. As research progresses, LFD-200 could potentially transform treatment paradigms for millions of patients worldwide who struggle with the limitations of current immunosuppressive therapies. The ability to deliver potent anti-inflammatory effects without systemic toxicity represents a crucial step forward in autoimmune disease management.
